559 related articles for article (PubMed ID: 31926856)
21. Differences in Repolarization Heterogeneity Among Heart Failure With Preserved Ejection Fraction Phenotypic Subgroups.
Oskouie SK; Prenner SB; Shah SJ; Sauer AJ
Am J Cardiol; 2017 Aug; 120(4):601-606. PubMed ID: 28651852
[TBL] [Abstract][Full Text] [Related]
22. Clinical phenogroup diversity and multiplicity: Impact on mechanisms of exercise intolerance in heart failure with preserved ejection fraction.
Larson K; Omar M; Sorimachi H; Omote K; Alogna A; Popovic D; Tada A; Doi S; Naser J; Reddy YNV; Redfield MM; Borlaug BA
Eur J Heart Fail; 2024 Mar; 26(3):564-577. PubMed ID: 38156712
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study.
Vazir A; Claggett B; Pitt B; Anand I; Sweitzer N; Fang J; Fleg J; Rouleau J; Shah S; Pfeffer MA; Solomon SD
JACC Heart Fail; 2017 Nov; 5(11):782-791. PubMed ID: 29032132
[TBL] [Abstract][Full Text] [Related]
24. Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.
Patel RB; Shah SJ; Fonarow GC; Butler J; Vaduganathan M
Curr Heart Fail Rep; 2017 Aug; 14(4):217-222. PubMed ID: 28647918
[TBL] [Abstract][Full Text] [Related]
25. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
Tromp J; Shen L; Jhund PS; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Køber L; Swedberg K; Zile MR; Pitt B; Lam CSP; McMurray JJV
J Am Coll Cardiol; 2019 Aug; 74(5):601-612. PubMed ID: 31370950
[TBL] [Abstract][Full Text] [Related]
26. Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension.
Tsujimoto T; Kajio H
J Am Heart Assoc; 2020 Dec; 9(23):e018827. PubMed ID: 33222584
[TBL] [Abstract][Full Text] [Related]
27. Association of Active and Passive Components of LV Diastolic Filling With Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Mechanistic Insights From Spironolactone Response.
Kosmala W; Przewlocka-Kosmala M; Marwick TH
JACC Cardiovasc Imaging; 2019 May; 12(5):784-794. PubMed ID: 29248640
[TBL] [Abstract][Full Text] [Related]
28. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.
Desai AS; Lewis EF; Li R; Solomon SD; Assmann SF; Boineau R; Clausell N; Diaz R; Fleg JL; Gordeev I; McKinlay S; O'Meara E; Shaburishvili T; Pitt B; Pfeffer MA
Am Heart J; 2011 Dec; 162(6):966-972.e10. PubMed ID: 22137068
[TBL] [Abstract][Full Text] [Related]
29. Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
Mitter SS; Shah SJ
Curr Atheroscler Rep; 2015 Nov; 17(11):64. PubMed ID: 26408016
[TBL] [Abstract][Full Text] [Related]
30. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.
Shah SJ; Heitner JF; Sweitzer NK; Anand IS; Kim HY; Harty B; Boineau R; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Lewis EF; Markov V; O'Meara E; Kobulia B; Shaburishvili T; Solomon SD; Pitt B; Pfeffer MA; Li R
Circ Heart Fail; 2013 Mar; 6(2):184-92. PubMed ID: 23258572
[TBL] [Abstract][Full Text] [Related]
31. Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction.
Kosmala W; Rojek A; Przewlocka-Kosmala M; Wright L; Mysiak A; Marwick TH
J Am Coll Cardiol; 2016 Oct; 68(17):1823-1834. PubMed ID: 27765184
[TBL] [Abstract][Full Text] [Related]
32. Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction.
Sandesara PB; Hammadah M; Samman-Tahhan A; Kelli HM; O'Neal WT
Clin Cardiol; 2017 Sep; 40(9):692-696. PubMed ID: 28444995
[TBL] [Abstract][Full Text] [Related]
33. Relationship of interleukin-16 with different phenogroups in acute heart failure with preserved ejection fraction.
Tamaki S; Sotomi Y; Nagai Y; Shutta R; Masuda D; Makino N; Yamashita S; Seo M; Yamada T; Nakagawa A; Yasumura Y; Nakagawa Y; Yano M; Hayashi T; Hikoso S; Nakatani D; Ohtani T; Sakata Y;
ESC Heart Fail; 2024 Apr; ():. PubMed ID: 38686566
[TBL] [Abstract][Full Text] [Related]
34. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
Vardeny O; Claggett B; Vaduganathan M; Beldhuis I; Rouleau J; O'Meara E; Anand IS; Shah SJ; Sweitzer NK; Fang JC; Desai AS; Lewis EF; Pitt B; Pfeffer MA; Solomon SD;
JACC Heart Fail; 2019 Dec; 7(12):1022-1028. PubMed ID: 31779923
[TBL] [Abstract][Full Text] [Related]
35. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Shen L; Jhund PS; Docherty KF; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
JACC Heart Fail; 2019 May; 7(5):418-427. PubMed ID: 30981744
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction.
Santos AB; Roca GQ; Claggett B; Sweitzer NK; Shah SJ; Anand IS; Fang JC; Zile MR; Pitt B; Solomon SD; Shah AM
Circ Heart Fail; 2016 Apr; 9(4):e002763. PubMed ID: 27056882
[TBL] [Abstract][Full Text] [Related]
37. Role of Ischemic Heart Disease in Major Adverse Renal and Cardiac Events Among Individuals With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).
Rahimi G; Tecson KM; Elsaid O; McCullough PA
Am J Cardiol; 2021 Mar; 142():91-96. PubMed ID: 33279481
[TBL] [Abstract][Full Text] [Related]
38. Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.
Hedman ÅK; Hage C; Sharma A; Brosnan MJ; Buckbinder L; Gan LM; Shah SJ; Linde CM; Donal E; Daubert JC; Mälarstig A; Ziemek D; Lund L
Heart; 2020 Mar; 106(5):342-349. PubMed ID: 31911501
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
Beldhuis IE; Myhre PL; Claggett B; Damman K; Fang JC; Lewis EF; O'Meara E; Pitt B; Shah SJ; Voors AA; Pfeffer MA; Solomon SD; Desai AS
JACC Heart Fail; 2019 Jan; 7(1):25-32. PubMed ID: 30606484
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease.
Tsujimoto T; Kajio H
Eur J Prev Cardiol; 2018 Aug; 25(12):1268-1277. PubMed ID: 29808753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
